{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:52:58Z","timestamp":1794653578561,"version":"4.9.1"},"reference-count":167,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1038\/s41582-023-00916-w","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T13:03:12Z","timestamp":1704718992000},"page":"84-98","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":133,"title":["Myasthenia gravis: the changing treatment landscape in the era of molecular therapies"],"prefix":"10.1038","volume":"20","author":[{"given":"Raffaele","family":"Iorio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"916_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mus.27832","volume":"68","author":"B Claytor","year":"2023","unstructured":"Claytor, B., Cho, S. M. & Li, Y. Myasthenic crisis. Muscle Nerve 68, 8\u201319 (2023).","journal-title":"Muscle Nerve"},{"key":"916_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus, N. E. et al. Myasthenia gravis. Nat. Rev. Dis. Prim. 5, 30 (2019).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"916_CR3","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ana.22312","volume":"69","author":"O Higuchi","year":"2011","unstructured":"Higuchi, O., Hamuro, J., Motomura, M. & Yamanashi, Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann. Neurol. 69, 418\u2013422 (2011).","journal-title":"Ann. Neurol."},{"key":"916_CR4","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/mus.25591","volume":"56","author":"Y Li","year":"2017","unstructured":"Li, Y. et al. Anti-LRP4 autoantibodies in Chinese patients with myasthenia gravis. Muscle Nerve 56, 938\u2013942 (2017).","journal-title":"Muscle Nerve"},{"key":"916_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","volume":"52","author":"P Zisimopoulou","year":"2014","unstructured":"Zisimopoulou, P. et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J. Autoimmun. 52, 139\u2013145 (2014).","journal-title":"J. Autoimmun."},{"key":"916_CR6","doi-asserted-by":"publisher","first-page":"577895","DOI":"10.1016\/j.jneuroim.2022.577895","volume":"368","author":"CJ Klein","year":"2022","unstructured":"Klein, C. J. et al. LRP4-IgG service line testing in seronegative myasthenia gravis and controls. J. Neuroimmunol. 368, 577895 (2022).","journal-title":"J. Neuroimmunol."},{"key":"916_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami, P. et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology 96, 114\u2013122 (2021).","journal-title":"Neurology"},{"key":"916_CR8","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1136\/ard.2008.092163","volume":"68","author":"D Huscher","year":"2009","unstructured":"Huscher, D. et al. Dose-related patterns of glucocorticoid-induced side effects. Ann. Rheum. Dis. 68, 1119\u20131124 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"916_CR9","doi-asserted-by":"publisher","first-page":"102712","DOI":"10.1016\/j.autrev.2020.102712","volume":"20","author":"AM Lascano","year":"2021","unstructured":"Lascano, A. M. & Lalive, P. H. Update in immunosuppressive therapy of myasthenia gravis. Autoimmun. Rev. 20, 102712 (2021).","journal-title":"Autoimmun. Rev."},{"key":"916_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0733-8619(05)70373-X","volume":"16","author":"H Machkhas","year":"1998","unstructured":"Machkhas, H & Harati, Y. Side effects of immunosuppressant therapies used in neurology. Neurol. Clin. 16, 171\u2013188 (1998).","journal-title":"Neurol. Clin."},{"key":"916_CR11","doi-asserted-by":"publisher","first-page":"175628561774913","DOI":"10.1177\/1756285617749134","volume":"11","author":"R Mantegazza","year":"2018","unstructured":"Mantegazza, R. & Antozzi, C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther. Adv. Neurol. Disord. 11, 1756285617749134 (2018).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"916_CR12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2108672119","volume":"119","author":"R Chia","year":"2022","unstructured":"Chia, R. et al. Identification of genetic risk loci and prioritization of genes and pathways for myasthenia gravis: a genome-wide association study. Proc. Natl Acad. Sci. USA 119, e2108672119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"916_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31951-8","volume":"13","author":"Y Yasumizu","year":"2022","unstructured":"Yasumizu, Y. et al. Myasthenia gravis-specific aberrant neuromuscular gene expression by medullary thymic epithelial cells in thymoma. Nat. Commun. 13, 4230 (2022).","journal-title":"Nat. Commun."},{"key":"916_CR14","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00401-021-02299-y","volume":"141","author":"F Ingelfinger","year":"2021","unstructured":"Ingelfinger, F. et al. Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature. Acta Neuropathol. 141, 901\u2013915 (2021).","journal-title":"Acta Neuropathol."},{"key":"916_CR15","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","volume":"11","author":"ML Fichtner","year":"2020","unstructured":"Fichtner, M. L., Jiang, R., Bourke, A., Nowak, R. J. & O\u2019Connor, K. C. Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology. Front. Immunol. 11, 776 (2020).","journal-title":"Front. Immunol."},{"key":"916_CR16","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/WCO.0000000000001088","volume":"35","author":"G Masi","year":"2022","unstructured":"Masi, G. & O\u2019Connor, K. C. Novel pathophysiological insights in autoimmune myasthenia gravis. Curr. Opin. Neurol. 35, 586\u2013596 (2022).","journal-title":"Curr. Opin. Neurol."},{"key":"916_CR17","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.immuni.2020.11.006","volume":"53","author":"RA Elsner","year":"2020","unstructured":"Elsner, R. A. & Shlomchik, M. J. Germinal center and extrafollicular B cell responses in vaccination, immunity, and autoimmunity. Immunity 53, 1136\u20131150 (2020).","journal-title":"Immunity"},{"key":"916_CR18","doi-asserted-by":"publisher","first-page":"686466","DOI":"10.3389\/fimmu.2021.686466","volume":"12","author":"C Zografou","year":"2021","unstructured":"Zografou, C., Vakrakou, A. G. & Stathopoulos, P. Short- and long-lived autoantibody-secreting cells in autoimmune neurological disorders. Front. Immunol. 12, 686466 (2021).","journal-title":"Front. Immunol."},{"key":"916_CR19","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.94263","volume":"2","author":"P Stathopoulos","year":"2017","unstructured":"Stathopoulos, P., Kumar, A., Nowak, R. J. & O\u2019Connor, K. C. Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis. JCI Insight 2, e94263 (2017).","journal-title":"JCI Insight"},{"key":"916_CR20","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3389\/fimmu.2020.00613","volume":"11","author":"M Marino","year":"2020","unstructured":"Marino, M. et al. Long-lasting rituximab-induced reduction of specific\u2013but not total\u2013IgG4 in MuSK-positive myasthenia gravis. Front. Immunol. 11, 613 (2020).","journal-title":"Front. Immunol."},{"key":"916_CR21","doi-asserted-by":"publisher","first-page":"605902","DOI":"10.3389\/fneur.2020.605902","volume":"11","author":"A Evoli","year":"2020","unstructured":"Evoli, A. & Iorio, R. Controversies in ocular myasthenia gravis. Front. Neurol. 11, 605902 (2020).","journal-title":"Front. Neurol."},{"key":"916_CR22","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.expneurol.2004.06.005","volume":"189","author":"HJ Kaminski","year":"2004","unstructured":"Kaminski, H. J., Li, Z., Richmonds, C., Lin, F. & Medof, M. E. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. Exp. Neurol. 189, 333\u2013342 (2004).","journal-title":"Exp. Neurol."},{"key":"916_CR23","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.3389\/fneur.2019.01343","volume":"10","author":"JT Vilquin","year":"2019","unstructured":"Vilquin, J. T., Bayer, A. C., Le Panse, R. & Berrih-Aknin, S. The muscle is not a passive target in myasthenia gravis. Front. Neurol. 10, 1343 (2019).","journal-title":"Front. Neurol."},{"key":"916_CR24","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","volume":"21","author":"AR Punga","year":"2022","unstructured":"Punga, A. R., Maddison, P., Heckmann, J. M., Guptill, J. T. & Evoli, A. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol. 21, 176\u2013188 (2022).","journal-title":"Lancet Neurol."},{"key":"916_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00281-021-00842-3","volume":"43","author":"A Marx","year":"2021","unstructured":"Marx, A. et al. Thymus and autoimmunity. Semin. Immunopathol. 43, 45\u201364 (2021).","journal-title":"Semin. Immunopathol."},{"key":"916_CR26","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/ana.23691","volume":"72","author":"PK Gregersen","year":"2012","unstructured":"Gregersen, P. K. et al. Risk for myasthenia gravis maps to a 151Pro->Ala change in TNIP1 and to human leukocyte antigen-B*08. Ann. Neurol. 72, 927\u2013935 (2012).","journal-title":"Ann. Neurol."},{"key":"916_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036603","volume":"7","author":"AH Maniaol","year":"2012","unstructured":"Maniaol, A. H. et al. Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population. PLoS ONE 7, e36603 (2012).","journal-title":"PLoS ONE"},{"key":"916_CR28","doi-asserted-by":"publisher","unstructured":"Iorio, R., Spagni, G. & Evoli, A. Paraneoplastic neurological syndromes associated with mediastinal tumors. Mediastinum\u00a0https:\/\/doi.org\/10.21037\/med.2018.01.03 (2018).","DOI":"10.21037\/med.2018.01.03"},{"key":"916_CR29","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1097\/JTO.0b013e31824cbb18","volume":"7","author":"R Iorio","year":"2012","unstructured":"Iorio, R., Evoli, A., Lauriola, L. & Batocchi, A. P. A B3 type-thymoma in a 7-year-old child with myasthenia gravis. J. Thorac. Oncol. 7, 937\u2013938 (2012).","journal-title":"J. Thorac. Oncol."},{"key":"916_CR30","doi-asserted-by":"publisher","first-page":"581097","DOI":"10.3389\/fnmol.2020.581097","volume":"13","author":"H Cetin","year":"2020","unstructured":"Cetin, H., Beeson, D., Vincent, A. & Webster, R. The structure, function, and physiology of the fetal and adult acetylcholine receptor in muscle. Front. Mol. Neurosci. 13, 581097 (2020).","journal-title":"Front. Mol. Neurosci."},{"key":"916_CR31","doi-asserted-by":"publisher","first-page":"13898","DOI":"10.1523\/JNEUROSCI.2833-09.2009","volume":"29","author":"J Luo","year":"2009","unstructured":"Luo, J. et al. Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity. J. Neurosci. 29, 13898\u201313908 (2009).","journal-title":"J. Neurosci."},{"key":"916_CR32","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.4049\/jimmunol.146.7.2245","volume":"146","author":"VA Lennon","year":"1991","unstructured":"Lennon, V. A., Lambert, E. H., Leiby, K. R., Okarma, T. B. & Talib, S. Recombinant human acetylcholine receptor \u0251-subunit induces chronic experimental autoimmune myasthenia gravis. J. Immunol. 146, 2245\u20132248 (1991).","journal-title":"J. Immunol."},{"key":"916_CR33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00401-023-02603-y","volume":"146","author":"MC Pham","year":"2023","unstructured":"Pham, M. C. et al. Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology. Acta Neuropathol. 146, 319\u2013336 (2023).","journal-title":"Acta Neuropathol."},{"key":"916_CR34","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/nri916","volume":"2","author":"A Vincent","year":"2002","unstructured":"Vincent, A. Unravelling the pathogenesis of myasthenia gravis. Nat. Rev. Immunol. 2, 797\u2013804 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"916_CR35","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/00005072-198003000-00005","volume":"39","author":"K Sahashi","year":"1980","unstructured":"Sahashi, K., Engel, A. G., Lambert, E. H. & Howard, F. M. Jr. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J. Neuropathol. Exp. Neurol. 39, 160\u2013172 (1980).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"916_CR36","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/00005072-197803000-00008","volume":"37","author":"K Sahashi","year":"1978","unstructured":"Sahashi, K., Engel, A. G., Linstrom, J. M., Lambert, E. H. & Lennon, V. A. Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis. J. Neuropathol. Exp. Neurol. 37, 212\u2013223 (1978).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"916_CR37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41577-019-0168-x","volume":"19","author":"ES Reis","year":"2019","unstructured":"Reis, E. S., Mastellos, D. C., Hajishengallis, G. & Lambris, J. D. New insights into the immune functions of complement. Nat. Rev. Immunol. 19, 503\u2013516 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"916_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00926-1","author":"DC Mastellos","year":"2023","unstructured":"Mastellos, D. C., Hajishengallis, G. & Lambris, J. D. A guide to complement biology, pathology and therapeutic opportunity. Nat. Rev. Immunol.\u00a0https:\/\/doi.org\/10.1038\/s41577-023-00926-1 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"916_CR39","first-page":"267","volume":"52","author":"AG Engel","year":"1977","unstructured":"Engel, A. G., Lambert, E. H. & Howard, F. M. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin. Proc. 52, 267\u2013280 (1977).","journal-title":"Mayo Clin. Proc."},{"key":"916_CR40","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1212\/WNL.29.2.179","volume":"29","author":"AG Engel","year":"1979","unstructured":"Engel, A. G. et al. Passively transferred experimental autoimmune myasthenia gravis. Sequential and quantitative study of the motor end-plate fine structure and ultrastructural localization of immune complexes (IgG and C3), and of the acetylcholine receptor. Neurology 29, 179\u2013188 (1979).","journal-title":"Neurology"},{"key":"916_CR41","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1365-2249.2006.03198.x","volume":"146","author":"J Chamberlain-Banoub","year":"2006","unstructured":"Chamberlain-Banoub, J., Neal, J. W., Mizuno, M., Harris, C. L. & Morgan, B. P. Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. Clin. Exp. Immunol. 146, 278\u2013286 (2006).","journal-title":"Clin. Exp. Immunol."},{"key":"916_CR42","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.4049\/jimmunol.171.7.3847","volume":"171","author":"E Tuzun","year":"2003","unstructured":"Tuzun, E., Scott, B. G., Goluszko, E., Higgs, S. & Christadoss, P. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J. Immunol. 171, 3847\u20133854 (2003).","journal-title":"J. Immunol."},{"key":"916_CR43","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.4049\/jimmunol.140.8.2589","volume":"140","author":"P Christadoss","year":"1988","unstructured":"Christadoss, P. C5 gene influences the development of murine myasthenia gravis. J. Immunol. 140, 2589\u20132592 (1988).","journal-title":"J. Immunol."},{"key":"916_CR44","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jneuroim.2006.10.014","volume":"182","author":"E Tuzun","year":"2007","unstructured":"Tuzun, E., Li, J., Saini, S. S., Yang, H. & Christadoss, P. Pros and cons of treating murine myasthenia gravis with anti-C1q antibody. J. Neuroimmunol. 182, 167\u2013176 (2007).","journal-title":"J. Neuroimmunol."},{"key":"916_CR45","doi-asserted-by":"publisher","first-page":"8562","DOI":"10.4049\/jimmunol.179.12.8562","volume":"179","author":"Y Zhou","year":"2007","unstructured":"Zhou, Y. et al. Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J. Immunol. 179, 8562\u20138567 (2007).","journal-title":"J. Immunol."},{"key":"916_CR46","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.4049\/jimmunol.142.8.2654","volume":"142","author":"G Biesecker","year":"1989","unstructured":"Biesecker, G. & Gomez, C. M. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. J. Immunol. 142, 2654\u20132659 (1989).","journal-title":"J. Immunol."},{"key":"916_CR47","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.omtm.2019.04.009","volume":"13","author":"LL Kusner","year":"2019","unstructured":"Kusner, L. L. et al. Investigational RNAi therapeutic targeting C5 is efficacious in pre-clinical models of myasthenia gravis. Mol. Ther. Methods Clin. Dev. 13, 484\u2013492 (2019).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"916_CR48","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jaut.2013.01.003","volume":"42","author":"R Huda","year":"2013","unstructured":"Huda, R., Tuzun, E. & Christadoss, P. Complement C2 siRNA mediated therapy of myasthenia gravis in mice. J. Autoimmun. 42, 94\u2013104 (2013).","journal-title":"J. Autoimmun."},{"key":"916_CR49","doi-asserted-by":"publisher","first-page":"948259","DOI":"10.3389\/fimmu.2022.948259","volume":"13","author":"Y Qi","year":"2022","unstructured":"Qi, Y., Zhang, R., Lu, Y., Zou, X. & Yang, W. Aire and Fezf2, two regulators in medullary thymic epithelial cells, control autoimmune diseases by regulating TSAs: partner or complementer? Front. Immunol. 13, 948259 (2022).","journal-title":"Front. Immunol."},{"key":"916_CR50","first-page":"597","volume":"20","author":"C Weigert","year":"1901","unstructured":"Weigert, C. Pathologisch-anatomischer Beitrag zur Erb\u2019schen Krankheit (myasthenia gravis). Neurologisches Centralblatt. Jg 20, 597\u2013601 (1901).","journal-title":"Neurologisches Centralblatt. Jg"},{"key":"916_CR51","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1602489","volume":"375","author":"GI Wolfe","year":"2016","unstructured":"Wolfe, G. I. et al. Randomized trial of thymectomy in myasthenia gravis. N. Engl. J. Med. 375, 511\u2013522 (2016).","journal-title":"N. Engl. J. Med."},{"key":"916_CR52","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.4049\/jimmunol.167.4.1935","volume":"167","author":"GP Sims","year":"2001","unstructured":"Sims, G. P., Shiono, H., Willcox, N. & Stott, D. I. Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis. J. Immunol. 167, 1935\u20131944 (2001).","journal-title":"J. Immunol."},{"key":"916_CR53","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0002-9440(10)62960-4","volume":"167","author":"P Bernasconi","year":"2005","unstructured":"Bernasconi, P. et al. Increased toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution. Am. J. Pathol. 167, 129\u2013139 (2005).","journal-title":"Am. J. Pathol."},{"key":"916_CR54","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.imbio.2015.12.007","volume":"221","author":"P Cavalcante","year":"2016","unstructured":"Cavalcante, P. et al. Increased expression of Toll-like receptors 7 and 9 in myasthenia gravis thymus characterized by active Epstein-Barr virus infection. Immunobiology 221, 516\u2013527 (2016).","journal-title":"Immunobiology"},{"key":"916_CR55","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00401-022-02493-6","volume":"144","author":"N Rose","year":"2022","unstructured":"Rose, N. et al. Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities. Acta Neuropathol. 144, 1005\u20131025 (2022).","journal-title":"Acta Neuropathol."},{"key":"916_CR56","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/0090-1229(85)90018-2","volume":"34","author":"Y Fujii","year":"1985","unstructured":"Fujii, Y., Monden, Y., Hashimoto, J., Nakahara, K. & Kawashima, Y. Acetylcholine receptor antibody-producing cells in thymus and lymph nodes in myasthenia gravis. Clin. Immunol. Immunopathol. 34, 141\u2013146 (1985).","journal-title":"Clin. Immunol. Immunopathol."},{"key":"916_CR57","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1212\/WNL.35.4.577","volume":"35","author":"Y Fujii","year":"1985","unstructured":"Fujii, Y., Monden, Y., Hashimoto, J., Nakahara, K. & Kawashima, Y. Acetylcholine receptor antibody production by bone marrow cells in a patient with myasthenia gravis. Neurology 35, 577\u2013579 (1985).","journal-title":"Neurology"},{"key":"916_CR58","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1212\/WNL.33.5.604","volume":"33","author":"RP Lisak","year":"1983","unstructured":"Lisak, R. P., Laramore, C., Zweiman, B. & Moskovitz, A. In vitro synthesis of antibodies to acetylcholine receptor by peripheral blood mononuclear cells of patients with myasthenia gravis. Neurology 33, 604\u2013608 (1983).","journal-title":"Neurology"},{"key":"916_CR59","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0092-8674(00)81251-9","volume":"85","author":"TM DeChiara","year":"1996","unstructured":"DeChiara, T. M. et al. The receptor tyrosine kinase MuSK is required for neuromuscular junction formation in vivo. Cell 85, 501\u2013512 (1996).","journal-title":"Cell"},{"key":"916_CR60","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1083\/jcb.200210156","volume":"161","author":"E Lacazette","year":"2003","unstructured":"Lacazette, E., Le Calvez, S., Gajendran, N. & Brenner, H. R. A novel pathway for MuSK to induce key genes in neuromuscular synapse formation. J. Cell Biol. 161, 727\u2013736 (2003).","journal-title":"J. Cell Biol."},{"key":"916_CR61","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cell.2008.10.002","volume":"135","author":"N Kim","year":"2008","unstructured":"Kim, N. et al. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 135, 334\u2013342 (2008).","journal-title":"Cell"},{"key":"916_CR62","doi-asserted-by":"publisher","first-page":"a009167","DOI":"10.1101\/cshperspect.a009167","volume":"5","author":"SJ Burden","year":"2013","unstructured":"Burden, S. J., Yumoto, N. & Zhang, W. The role of MuSK in synapse formation and neuromuscular disease. Cold Spring Harb. Perspect. Biol. 5, a009167 (2013).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"916_CR63","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1007\/s00018-012-1209-9","volume":"70","author":"Y Zong","year":"2013","unstructured":"Zong, Y. & Jin, R. Structural mechanisms of the agrin-LRP4-MuSK signaling pathway in neuromuscular junction differentiation. Cell Mol. Life Sci. 70, 3077\u20133088 (2013).","journal-title":"Cell Mol. Life Sci."},{"key":"916_CR64","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1093\/brain\/awg223","volume":"126","author":"A Evoli","year":"2003","unstructured":"Evoli, A. et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 126, 2304\u20132311 (2003).","journal-title":"Brain"},{"key":"916_CR65","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/brain\/awl095","volume":"129","author":"ME Farrugia","year":"2006","unstructured":"Farrugia, M. E. et al. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 129, 1481\u20131492 (2006).","journal-title":"Brain"},{"key":"916_CR66","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/cen3.12173","volume":"6","author":"A Evoli","year":"2015","unstructured":"Evoli, A. & Iorio, R. Characteristics of myasthenia gravis with antibodies to muscle\u2010specific kinase and low\u2010density lipoprotein\u2010related receptor protein 4. Clin. Exp. Neuroimmunol. 6, 40\u201348 (2015).","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"916_CR67","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/nyas.13518","volume":"1412","author":"A Evoli","year":"2018","unstructured":"Evoli, A. et al. Myasthenia gravis with antibodies to MuSK: an update. Ann. N. Y. Acad. Sci. 1412, 82\u201389 (2018).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"916_CR68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080695","volume":"8","author":"I Koneczny","year":"2013","unstructured":"Koneczny, I., Cossins, J., Waters, P., Beeson, D. & Vincent, A. MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters. PLoS ONE 8, e80695 (2013).","journal-title":"PLoS ONE"},{"key":"916_CR69","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1126\/science.1144603","volume":"317","author":"M van der Neut Kolfschoten","year":"2007","unstructured":"van der Neut Kolfschoten, M. et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317, 1554\u20131557 (2007).","journal-title":"Science"},{"key":"916_CR70","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000547","volume":"6","author":"MG Huijbers","year":"2019","unstructured":"Huijbers, M. G. et al. MuSK myasthenia gravis monoclonal antibodies: valency dictates pathogenicity. Neurol. Neuroimmunol. Neuroinflamm 6, e547 (2019).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"key":"916_CR71","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/jnnp-2022-329284","volume":"93","author":"V Damato","year":"2022","unstructured":"Damato, V. et al. Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 93, 995\u20131000 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"916_CR72","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00401-020-02147-5","volume":"139","author":"S Hoffmann","year":"2020","unstructured":"Hoffmann, S. et al. Complement deposition at the neuromuscular junction in seronegative myasthenia gravis. Acta Neuropathol. 139, 1119\u20131122 (2020).","journal-title":"Acta Neuropathol."},{"key":"916_CR73","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s10072-019-03746-1","volume":"40","author":"A Evoli","year":"2019","unstructured":"Evoli, A. et al. Italian recommendations for the diagnosis and treatment of myasthenia gravis. Neurol. Sci. 40, 1111\u20131124 (2019).","journal-title":"Neurol. Sci."},{"key":"916_CR74","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cen3.12739","volume":"14","author":"H Murai","year":"2023","unstructured":"Murai, H. et al. The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert\u2013Eaton myasthenic syndrome. Clin. Exp. Neuroimmunol. 14, 19\u201327 (2023).","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"916_CR75","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","volume":"263","author":"N Melzer","year":"2016","unstructured":"Melzer, N. et al. Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J. Neurol. 263, 1473\u20131494 (2016).","journal-title":"J. Neurol."},{"key":"916_CR76","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.clinph.2021.04.019","volume":"132","author":"A Modoni","year":"2021","unstructured":"Modoni, A., Mastrorosa, A., Spagni, G. & Evoli, A. Cholinergic hyperactivity in patients with myasthenia gravis with MuSK antibodies: a neurophysiological study. Clin. Neurophysiol. 132, 1845\u20131849 (2021).","journal-title":"Clin. Neurophysiol."},{"key":"916_CR77","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1212\/WNL.0000000000002466","volume":"86","author":"A Evoli","year":"2016","unstructured":"Evoli, A., Alboini, P. E., Damato, V. & Iorio, R. 3,4-Diaminopyridine may improve myasthenia gravis with MuSK antibodies. Neurology 86, 1070\u20131071 (2016).","journal-title":"Neurology"},{"key":"916_CR78","doi-asserted-by":"publisher","first-page":"662856","DOI":"10.3389\/fneur.2021.662856","volume":"12","author":"TS Ipe","year":"2021","unstructured":"Ipe, T. S., Davis, A. R. & Raval, J. S. Therapeutic plasma exchange in myasthenia gravis: a systematic literature review and meta-analysis of comparative evidence. Front. Neurol. 12, 662856 (2021).","journal-title":"Front. Neurol."},{"key":"916_CR79","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/j.1468-1331.2006.01382.x","volume":"13","author":"C Rozsa","year":"2006","unstructured":"Rozsa, C., Lovas, G., Fornadi, L., Szabo, G. & Komoly, S. Safety of long-term combined immunosuppressive treatment in myasthenia gravis \u2013 analysis of adverse effects of 163 patients. Eur. J. Neurol. 13, 947\u2013952 (2006).","journal-title":"Eur. J. Neurol."},{"key":"916_CR80","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1111\/ene.14730","volume":"28","author":"J Verwijst","year":"2021","unstructured":"Verwijst, J., Westerberg, E. & Punga, A. R. Cancer in myasthenia gravis subtypes in relation to immunosuppressive treatment and acetylcholine receptor antibodies: a Swedish nationwide register study. Eur. J. Neurol. 28, 1706\u20131715 (2021).","journal-title":"Eur. J. Neurol."},{"key":"916_CR81","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1038\/sj.leu.2402639","volume":"16","author":"C Kosmas","year":"2002","unstructured":"Kosmas, C., Stamatopoulos, K., Stavroyianni, N., Tsavaris, N. & Papadaki, T. Anti-CD20-based therapy of B cell lymphoma: state of the art. Leukemia 16, 2004\u20132015 (2002).","journal-title":"Leukemia"},{"key":"916_CR82","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","volume":"20","author":"DSW Lee","year":"2021","unstructured":"Lee, D. S. W., Rojas, O. L. & Gommerman, J. L. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat. Rev. Drug. Discov. 20, 179\u2013199 (2021).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"916_CR83","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.2147\/DDDT.S139248","volume":"11","author":"T Schioppo","year":"2017","unstructured":"Schioppo, T. & Ingegnoli, F. Current perspective on rituximab in rheumatic diseases. Drug. Des. Devel Ther. 11, 2891\u20132904 (2017).","journal-title":"Drug. Des. Devel Ther."},{"key":"916_CR84","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/practneurol-2018-001899","volume":"19","author":"DH Whittam","year":"2019","unstructured":"Whittam, D. H. et al. Rituximab in neurological disease: principles, evidence and practice. Pract. Neurol. 19, 5\u201320 (2019).","journal-title":"Pract. Neurol."},{"key":"916_CR85","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","volume":"105","author":"G Pavlasova","year":"2020","unstructured":"Pavlasova, G. & Mraz, M. The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy. Haematologica 105, 1494\u20131506 (2020).","journal-title":"Haematologica"},{"key":"916_CR86","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2021342118","volume":"118","author":"K Klasener","year":"2021","unstructured":"Klasener, K. et al. CD20 as a gatekeeper of the resting state of human B cells. Proc. Natl Acad. Sci. USA 118, e2021342118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"916_CR87","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/rheumatology\/kel148","volume":"46","author":"MJ Leandro","year":"2007","unstructured":"Leandro, M. J., Cooper, N., Cambridge, G., Ehrenstein, M. R. & Edwards, J. C. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology 46, 29\u201336 (2007).","journal-title":"Rheumatology"},{"key":"916_CR88","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1111\/ajt.12220","volume":"13","author":"EG Kamburova","year":"2013","unstructured":"Kamburova, E. G. et al. A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function. Am. J. Transpl. 13, 1503\u20131511 (2013).","journal-title":"Am. J. Transpl."},{"key":"916_CR89","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","volume":"262","author":"R Iorio","year":"2015","unstructured":"Iorio, R., Damato, V., Alboini, P. E. & Evoli, A. Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J. Neurol. 262, 1115\u20131119 (2015).","journal-title":"J. Neurol."},{"key":"916_CR90","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1111\/ene.14391","volume":"27","author":"A Dos Santos","year":"2020","unstructured":"Dos Santos, A. et al. Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real-life study. Eur. J. Neurol. 27, 2277\u20132285 (2020).","journal-title":"Eur. J. Neurol."},{"key":"916_CR91","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1212\/WNL.0000000000004341","volume":"89","author":"MK Hehir","year":"2017","unstructured":"Hehir, M. K. et al. Rituximab as treatment for anti-MuSK myasthenia gravis: multicenter blinded prospective review. Neurology 89, 1069\u20131077 (2017).","journal-title":"Neurology"},{"key":"916_CR92","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00415-019-09191-6","volume":"266","author":"R Topakian","year":"2019","unstructured":"Topakian, R. et al. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria. J. Neurol. 266, 699\u2013706 (2019).","journal-title":"J. Neurol."},{"key":"916_CR93","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1001\/jamaneurol.2020.0851","volume":"77","author":"S Brauner","year":"2020","unstructured":"Brauner, S. et al. Comparison between rituximab treatment for new-onset generalized myasthenia gravis and refractory generalized myasthenia gravis. JAMA Neurol. 77, 974\u2013981 (2020).","journal-title":"JAMA Neurol."},{"key":"916_CR94","first-page":"e376","volume":"98","author":"RJ Nowak","year":"2021","unstructured":"Nowak, R. J. et al. Phase 2 trial of rituximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: the BeatMG study. Neurology 98, e376\u2013e389 (2021).","journal-title":"Neurology"},{"key":"916_CR95","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jamaneurol.2022.2887","volume":"79","author":"F Piehl","year":"2022","unstructured":"Piehl, F. et al. Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial. JAMA Neurol. 79, 1105\u20131112 (2022).","journal-title":"JAMA Neurol."},{"key":"916_CR96","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.136471","volume":"5","author":"R Jiang","year":"2020","unstructured":"Jiang, R. et al. Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia gravis relapses. JCI Insight 5, e136471 (2020).","journal-title":"JCI Insight"},{"key":"916_CR97","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser, S. L. et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. 376, 221\u2013234 (2017).","journal-title":"N. Engl. J. Med."},{"key":"916_CR98","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser, S. L. et al. Ofatumumab versus teriflunomide in multiple sclerosis. N. Engl. J. Med. 383, 546\u2013557 (2020).","journal-title":"N. Engl. J. Med."},{"key":"916_CR99","doi-asserted-by":"publisher","first-page":"326","DOI":"10.4161\/mabs.1.4.8895","volume":"1","author":"B Zhang","year":"2009","unstructured":"Zhang, B. Ofatumumab. MAbs 1, 326\u2013331 (2009).","journal-title":"MAbs"},{"key":"916_CR100","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJMoa2201904","volume":"387","author":"L Steinman","year":"2022","unstructured":"Steinman, L. et al. Ublituximab versus teriflunomide in relapsing multiple sclerosis. N. Engl. J. Med. 387, 704\u2013714 (2022).","journal-title":"N. Engl. J. Med."},{"key":"916_CR101","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/leu.2013.240","volume":"28","author":"M Le Garff-Tavernier","year":"2014","unstructured":"Le Garff-Tavernier, M. et al. Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion. Leukemia 28, 230\u2013233 (2014).","journal-title":"Leukemia"},{"key":"916_CR102","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nrrheum.2009.184","volume":"5","author":"TF Tedder","year":"2009","unstructured":"Tedder, T. F. CD19: a promising B cell target for rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 572\u2013577 (2009).","journal-title":"Nat. Rev. Rheumatol."},{"key":"916_CR103","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree, B. A. C. et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet 394, 1352\u20131363 (2019).","journal-title":"Lancet"},{"key":"916_CR104","doi-asserted-by":"publisher","unstructured":"Khaled, A., Kaminski, H. J. & Howard, J. F. Complement inhibitor therapy for myasthenia gravis. Front. Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.00917 (2020).","DOI":"10.3389\/fimmu.2020.00917"},{"key":"916_CR105","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1146\/annurev-immunol-032713-120154","volume":"32","author":"VM Holers","year":"2014","unstructured":"Holers, V. M. Complement and its receptors: new insights into human disease. Annu. Rev. Immunol. 32, 433\u2013459 (2014).","journal-title":"Annu. Rev. Immunol."},{"key":"916_CR106","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00281-017-0644-y","volume":"40","author":"J Killick","year":"2018","unstructured":"Killick, J., Morisse, G., Sieger, D. & Astier, A. L. Complement as a regulator of adaptive immunity. Semin. Immunopathol. 40, 37\u201348 (2018).","journal-title":"Semin. Immunopathol."},{"key":"916_CR107","doi-asserted-by":"publisher","first-page":"108830","DOI":"10.1016\/j.clim.2021.108830","volume":"231","author":"Y Li","year":"2021","unstructured":"Li, Y. et al. Cellular changes in eculizumab early responders with generalized myasthenia gravis. Clin. Immunol. 231, 108830 (2021).","journal-title":"Clin. Immunol."},{"key":"916_CR108","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1365-2125.2009.03491.x","volume":"68","author":"EA Dubois","year":"2009","unstructured":"Dubois, E. A. & Cohen, A. F. Eculizumab. Br. J. Clin. Pharmacol. 68, 318\u2013319 (2009).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"916_CR109","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen, P. et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 355, 1233\u20131243 (2006).","journal-title":"N. Engl. J. Med."},{"key":"916_CR110","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre, C. M. et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 368, 2169\u20132181 (2013).","journal-title":"N. Engl. J. Med."},{"key":"916_CR111","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr.","year":"2017","unstructured":"Howard, J. F. Jr. et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 16, 976\u2013986 (2017).","journal-title":"Lancet Neurol."},{"key":"916_CR112","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock, S. J. et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N. Engl. J. Med. 381, 614\u2013625 (2019).","journal-title":"N. Engl. J. Med."},{"key":"916_CR113","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1212\/WNL.0000000000011207","volume":"96","author":"R Mantegazza","year":"2021","unstructured":"Mantegazza, R. et al. Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extension. Neurology 96, e610\u2013e618 (2021).","journal-title":"Neurology"},{"key":"916_CR114","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1007\/s11136-019-02148-2","volume":"28","author":"H Andersen","year":"2019","unstructured":"Andersen, H. et al. Eculizumab improves fatigue in refractory generalized myasthenia gravis. Qual. Life Res. 28, 2247\u20132254 (2019).","journal-title":"Qual. Life Res."},{"key":"916_CR115","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","volume":"66","author":"LA McNamara","year":"2017","unstructured":"McNamara, L. A. et al. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. MMWR Morb. Mortal. Wkly. Rep. 66, 734\u2013737 (2017).","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"916_CR116","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241989","volume":"15","author":"CH Bozio","year":"2020","unstructured":"Bozio, C. H., Isenhour, C. & McNamara, L. A. Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States. PLoS ONE 15, e0241989 (2020).","journal-title":"PLoS ONE"},{"key":"916_CR117","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/ndt\/gfaa140.MO020","volume":"35","author":"A G\u00e4ckler","year":"2020","unstructured":"G\u00e4ckler, A. et al. Failure of first meningococcal vaccination in patients with atypical haemolytic uraemic syndrome treated with eculizumab. Nephrol. Dial. Transpl. 35, 298\u2013303 (2020).","journal-title":"Nephrol. Dial. Transpl."},{"key":"916_CR118","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1056\/NEJMoa1311084","volume":"370","author":"J Nishimura","year":"2014","unstructured":"Nishimura, J. et al. Genetic variants in C5 and poor response to eculizumab. N. Engl. J. Med. 370, 632\u2013639 (2014).","journal-title":"N. Engl. J. Med."},{"key":"916_CR119","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1007\/s00415-023-11617-1","volume":"270","author":"T Vu","year":"2023","unstructured":"Vu, T. et al. Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis. J. Neurol. 270, 3129\u20133137 (2023).","journal-title":"J. Neurol."},{"key":"916_CR120","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","volume":"133","author":"JW Lee","year":"2019","unstructured":"Lee, J. W. et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood 133, 530\u2013539 (2019).","journal-title":"Blood"},{"key":"916_CR121","first-page":"EVIDoa2100066","volume":"1","author":"V Tuan","year":"2022","unstructured":"Tuan, V. et al. Terminal complement inhibitor ravulizumab in generalized myasthenia gravis. NEJM Evid. 1, EVIDoa2100066 (2022).","journal-title":"NEJM Evid."},{"key":"916_CR122","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1016\/j.jinf.2021.03.014","volume":"82","author":"P Navarro-Carrera","year":"2021","unstructured":"Navarro-Carrera, P., Garcia-Rodriguez, J. & Cendejas-Bueno, E. Detection of Neisseria meningitidis in a patient receiving ravulizumab by the FilmArray(R) Meningitis\/Encephalitis Panel \u2013 a case report. J. Infect. 82, e22\u2013e23 (2021).","journal-title":"J. Infect."},{"key":"916_CR123","doi-asserted-by":"publisher","first-page":"1213920","DOI":"10.3389\/fimmu.2023.1213920","volume":"14","author":"GQ Tang","year":"2023","unstructured":"Tang, G. Q. et al. Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation. Front. Immunol. 14, 1213920 (2023).","journal-title":"Front. Immunol."},{"key":"916_CR124","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41573-019-0031-6","volume":"18","author":"DC Mastellos","year":"2019","unstructured":"Mastellos, D. C., Ricklin, D. & Lambris, J. D. Clinical promise of next-generation complement therapeutics. Nat. Rev. Drug. Discov. 18, 707\u2013729 (2019).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"916_CR125","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","volume":"22","author":"JF Howard Jr","year":"2023","unstructured":"Howard, J. F. Jr et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 22, 395\u2013406 (2023).","journal-title":"Lancet Neurol."},{"key":"916_CR126","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","volume":"23","author":"M Pyzik","year":"2023","unstructured":"Pyzik, M., Kozicky, L. K., Gandhi, A. K. & Blumberg, R. S. The therapeutic age of the neonatal Fc receptor. Nat. Rev. Immunol. 23, 415\u2013432 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"916_CR127","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1172\/JCI106279","volume":"49","author":"A Morell","year":"1970","unstructured":"Morell, A., Terry, W. D. & Waldmann, T. A. Metabolic properties of IgG subclasses in man. J. Clin. Invest. 49, 673\u2013680 (1970).","journal-title":"J. Clin. Invest."},{"key":"916_CR128","doi-asserted-by":"publisher","first-page":"eaax9586","DOI":"10.1126\/sciadv.aax9586","volume":"5","author":"LJ Blumberg","year":"2019","unstructured":"Blumberg, L. J. et al. Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses. Sci. Adv. 5, eaax9586 (2019).","journal-title":"Sci. Adv."},{"key":"916_CR129","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3389\/fimmu.2014.00408","volume":"5","author":"K Baker","year":"2014","unstructured":"Baker, K., Rath, T., Pyzik, M. & Blumberg, R. S. The role of FcRn in antigen presentation. Front. Immunol. 5, 408 (2014).","journal-title":"Front. Immunol."},{"key":"916_CR130","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1084\/jem.20092140","volume":"207","author":"SL Jongbloed","year":"2010","unstructured":"Jongbloed, S. L. et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J. Exp. Med. 207, 1247\u20131260 (2010).","journal-title":"J. Exp. Med."},{"key":"916_CR131","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI97911","volume":"128","author":"P Ulrichts","year":"2018","unstructured":"Ulrichts, P. et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans. J. Clin. Invest. 128, 4372\u20134386 (2018).","journal-title":"J. Clin. Invest."},{"key":"916_CR132","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr.","year":"2021","unstructured":"Howard, J. F. Jr. et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 20, 526\u2013536 (2021).","journal-title":"Lancet Neurol."},{"key":"916_CR133","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s40265-023-01933-1","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy, S. M. Rozanolixizumab: first approval. Drugs 83, 1341\u20131347 (2023).","journal-title":"Drugs"},{"key":"916_CR134","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril, V. et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 22, 383\u2013394 (2023).","journal-title":"Lancet Neurol."},{"key":"916_CR135","doi-asserted-by":"publisher","first-page":"eaan1208","DOI":"10.1126\/scitranslmed.aan1208","volume":"9","author":"P Kiessling","year":"2017","unstructured":"Kiessling, P. et al. The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study. Sci. Transl. Med. 9, eaan1208 (2017).","journal-title":"Sci. Transl. Med."},{"key":"916_CR136","doi-asserted-by":"publisher","unstructured":"Guptill, J. A. et al. Vivacity-MG: a phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of nipocalimab administered to adults with generalized myasthenia gravis [abstract]. Neurology https:\/\/doi.org\/10.1212\/WNL.96.15_supplement.2157 (2021).","DOI":"10.1212\/WNL.96.15_supplement.2157"},{"key":"916_CR137","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1111\/cts.13019","volume":"14","author":"DYH Yap","year":"2021","unstructured":"Yap, D. Y. H. et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers. Clin. Transl. Sci. 14, 1769\u20131779 (2021).","journal-title":"Clin. Transl. Sci."},{"key":"916_CR138","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s40120-022-00345-9","volume":"11","author":"C Yan","year":"2022","unstructured":"Yan, C. et al. Therapeutic effects of batoclimab in Chinese patients with generalized myasthenia gravis: a double-blinded, randomized, placebo-controlled phase II study. Neurol. Ther. 11, 815\u2013834 (2022).","journal-title":"Neurol. Ther."},{"key":"916_CR139","doi-asserted-by":"publisher","first-page":"eabm8389","DOI":"10.1126\/sciimmunol.abm8389","volume":"7","author":"MJ Robinson","year":"2022","unstructured":"Robinson, M. J. et al. Long-lived plasma cells accumulate in the bone marrow at a constant rate from early in an immune response. Sci. Immunol. 7, eabm8389 (2022).","journal-title":"Sci. Immunol."},{"key":"916_CR140","doi-asserted-by":"publisher","first-page":"965","DOI":"10.3389\/fimmu.2019.00965","volume":"10","author":"SM Lightman","year":"2019","unstructured":"Lightman, S. M., Utley, A. & Lee, K. P. Survival of long-lived plasma cells (LLPC): piecing together the puzzle. Front. Immunol. 10, 965 (2019).","journal-title":"Front. Immunol."},{"key":"916_CR141","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3389\/fimmu.2013.00494","volume":"4","author":"M Mahevas","year":"2013","unstructured":"Mahevas, M., Michel, M., Weill, J. C. & Reynaud, C. A. Long-lived plasma cells in autoimmunity: lessons from B-cell depleting therapy. Front. Immunol. 4, 494 (2013).","journal-title":"Front. Immunol."},{"key":"916_CR142","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/imr.12895","volume":"296","author":"MJ Robinson","year":"2020","unstructured":"Robinson, M. J., Webster, R. H. & Tarlinton, D. M. How intrinsic and extrinsic regulators of plasma cell survival might intersect for durable humoral immunity. Immunol. Rev. 296, 87\u2013103 (2020).","journal-title":"Immunol. Rev."},{"key":"916_CR143","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","volume":"14","author":"EE Manasanch","year":"2017","unstructured":"Manasanch, E. E. & Orlowski, R. Z. Proteasome inhibitors in cancer therapy. Nat. Rev. Clin. Oncol. 14, 417\u2013433 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"916_CR144","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel, J. F. et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359, 906\u2013917 (2008).","journal-title":"N. Engl. J. Med."},{"key":"916_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0298-1","volume":"10","author":"S Zhang","year":"2020","unstructured":"Zhang, S. et al. Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis. Blood Cancer J. 10, 33 (2020).","journal-title":"Blood Cancer J."},{"key":"916_CR146","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.4049\/jimmunol.1002539","volume":"186","author":"AM Gomez","year":"2011","unstructured":"Gomez, A. M. et al. Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J. Immunol. 186, 2503\u20132513 (2011).","journal-title":"J. Immunol."},{"key":"916_CR147","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2147\/tcrm.2006.2.3.271","volume":"2","author":"A Field-Smith","year":"2006","unstructured":"Field-Smith, A., Morgan, G. J. & Davies, F. E. Bortezomib (Velcadetrade) in the treatment of multiple myeloma. Ther. Clin. Risk Manag. 2, 271\u2013279 (2006).","journal-title":"Ther. Clin. Risk Manag."},{"key":"916_CR148","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","volume":"98","author":"D Siegel","year":"2013","unstructured":"Siegel, D. et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 98, 1753\u20131761 (2013).","journal-title":"Haematologica"},{"key":"916_CR149","doi-asserted-by":"publisher","first-page":"106507","DOI":"10.1016\/j.bioorg.2023.106507","volume":"135","author":"G Zeng","year":"2023","unstructured":"Zeng, G. et al. Recent advances and future perspectives of noncompetitive proteasome inhibitors. Bioorg. Chem. 135, 106507 (2023).","journal-title":"Bioorg. Chem."},{"key":"916_CR150","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/bs.ai.2015.12.006","volume":"130","author":"JC Yang","year":"2016","unstructured":"Yang, J. C. & Rosenberg, S. A. Adoptive T-cell therapy for cancer. Adv. Immunol. 130, 279\u2013294 (2016).","journal-title":"Adv. Immunol."},{"key":"916_CR151","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C. & Sterner, R. M. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 11, 69 (2021).","journal-title":"Blood Cancer J."},{"key":"916_CR152","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/hon.2591","volume":"37","author":"D Sermer","year":"2019","unstructured":"Sermer, D. & Brentjens, R. CAR T-cell therapy: full speed ahead. Hematol. Oncol. 37, 95\u2013100\u00a0(2019).","journal-title":"Hematol. Oncol."},{"key":"916_CR153","doi-asserted-by":"publisher","first-page":"797440","DOI":"10.3389\/fbioe.2022.797440","volume":"10","author":"A Alnefaie","year":"2022","unstructured":"Alnefaie, A. et al. Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions. Front. Bioeng. Biotechnol. 10, 797440 (2022).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"916_CR154","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/nbt.3670","volume":"34","author":"L Chatenoud","year":"2016","unstructured":"Chatenoud, L. Precision medicine for autoimmune disease. Nat. Biotechnol. 34, 930\u2013932 (2016).","journal-title":"Nat. Biotechnol."},{"key":"916_CR155","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","volume":"22","author":"V Granit","year":"2023","unstructured":"Granit, V. et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study. Lancet Neurol. 22, 578\u2013590 (2023).","journal-title":"Lancet Neurol."},{"key":"916_CR156","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht, C. T. et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353, 179\u2013184 (2016).","journal-title":"Science"},{"key":"916_CR157","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","volume":"353","author":"S Oh","year":"2023","unstructured":"Oh, S. et al. Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. Nat. Biotechnol. 353, 1229\u20131238 (2023).","journal-title":"Nat. Biotechnol."},{"key":"916_CR158","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","volume":"3","author":"CL Bonifant","year":"2016","unstructured":"Bonifant, C. L., Jackson, H. J., Brentjens, R. J. & Curran, K. J. Toxicity and management in CAR T-cell therapy. Mol. Ther. Oncolytics 3, 16011 (2016).","journal-title":"Mol. Ther. Oncolytics"},{"key":"916_CR159","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41580-023-00615-w","volume":"24","author":"A Baysoy","year":"2023","unstructured":"Baysoy, A., Bai, Z., Satija, R. & Fan, R. The technological landscape and applications of single-cell multi-omics. Nat. Rev. Mol. Cell Biol. 24, 695\u2013713 (2023).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"916_CR160","doi-asserted-by":"publisher","first-page":"175628642093203","DOI":"10.1177\/1756286420932035","volume":"13","author":"V Velez-Santamaria","year":"2020","unstructured":"Velez-Santamaria, V. et al. Eculizumab as a promising treatment in thymoma-associated myasthenia gravis. Ther. Adv. Neurol. Disord. 13, 1756286420932035 (2020).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"916_CR161","doi-asserted-by":"publisher","first-page":"6152","DOI":"10.1007\/s00415-022-11222-8","volume":"269","author":"CMM Strano","year":"2022","unstructured":"Strano, C. M. M. et al. Eculizumab as a fast-acting rescue therapy in a refractory myasthenic crisis: a case report. J. Neurol. 269, 6152\u20136154 (2022).","journal-title":"J. Neurol."},{"key":"916_CR162","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.1007\/s10072-023-06900-y","volume":"44","author":"C Vinciguerra","year":"2023","unstructured":"Vinciguerra, C. et al. Starting eculizumab as rescue therapy in refractory myasthenic crisis. Neurol. Sci. 44, 3707\u20133709 (2023).","journal-title":"Neurol. Sci."},{"key":"916_CR163","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124299","volume":"4","author":"CY Lin","year":"2019","unstructured":"Lin, C. Y. et al. iPSC-derived functional human neuromuscular junctions model the pathophysiology of neuromuscular diseases. JCI Insight 4, e124299 (2019).","journal-title":"JCI Insight"},{"key":"916_CR164","first-page":"119","volume":"28","author":"JA Tice","year":"2022","unstructured":"Tice, J. A. et al. The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis. J. Manag. Care Spec. Pharm. 28, 119\u2013124 (2022).","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"916_CR165","doi-asserted-by":"publisher","first-page":"7","DOI":"10.25122\/jml-2020-0145","volume":"14","author":"AM Bubuioc","year":"2021","unstructured":"Bubuioc, A. M., Kudebayeva, A., Turuspekova, S., Lisnic, V. & Leone, M. A. The epidemiology of myasthenia gravis. J. Med. Life 14, 7\u201316 (2021).","journal-title":"J. Med. Life"},{"key":"916_CR166","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1212\/WNL.0000000000207278","volume":"101","author":"JT Guptill","year":"2023","unstructured":"Guptill, J. T. et al. Addressing outcome measure variability in myasthenia gravis clinical trials. Neurology 101, 442\u2013451 (2023).","journal-title":"Neurology"},{"key":"916_CR167","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/WNL.55.1.16","volume":"55","author":"A Jaretzki 3rd","year":"2000","unstructured":"Jaretzki, A. 3rd et al. Myasthenia gravis: recommendations for clinical research standards. Task force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55, 16\u201323 (2000).","journal-title":"Neurology"}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-023-00916-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-023-00916-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-023-00916-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T09:36:54Z","timestamp":1707125814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-023-00916-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":167,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["916"],"URL":"https:\/\/doi.org\/10.1038\/s41582-023-00916-w","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"assertion":[{"value":"6 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author has received consultancy fees and speaker honoraria from Alexion, Argenx and UCB.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}